Arcadia Biosciences Q3 revenue falls

Arcadia Biosciences

07/11/2025 21:15

Overview

Arcadia Q3 revenue declines 15% yr/yr, missing analyst expectations

Net income for Q3 beats analyst estimates, driven by unrealized gain on ABVE stock

Arcadia maintains gross profit margins above 30% for 11th consecutive quarter

Outlook

Arcadia is pursuing resolution of outstanding balance with Above Food Ingredients Inc.

Company faces uncertainty in timing of Roosevelt Resources transaction due to government shutdown

Result Drivers

ZOLA REVENUE GROWTH - Year-to-date Zola revenues increased 26% due to expanded distribution and higher sales volumes

GROSS MARGINS - Gross profit margins exceeded 30% for the 11th consecutive quarter, supported by reduced SG&A expenses

REVENUE DECLINE FACTORS - Q3 revenue decline attributed to absence of GLA oil sales and lack of incremental sales to a major customer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$1.3 mln
$1.9 mln (1 Analyst)
Q3 Net Income
Beat
$856,000
-$660,000 (1 Analyst)
Q3 Operating Expenses
$2.45 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the food processing peer group is "buy"

Wall Street's median 12-month price target for Arcadia Biosciences Inc is $12.00, about 67.5% above its November 6 closing price of $3.90

Press Release: ID:nGNX1pv4g3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)